Sage Journals: Discover world-class research

Abstract

This article summarizes a presentation made at the joint BIA/MHRA conference, “Challenges of Development of Targeted Agents and Companion Diagnostics,” in London in March 2011. It focuses on the challenges the pharmaceutical industry is facing with the development of targeted agents in the field of oncology, in parallel with the challenges associated with the identification and development of the necessary diagnostic tools to support patient selection for personalized therapy. This article will encompass clinical, technical, and regulatory aspects.

Keywords

personalized medicine companion diagnostic test predictive biomarker targeted therapy

Get full access to this article

View all access options for this article.

References

Von Hoff

Stephenson

Jr Rosen

Pilot study using molecular profiling of patients’ tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol. 2010;28:4877–4883.

Personalized Medicine Coalition. Priorities for Personalized Medicine. President's Council of Advisors on Science and Technology. 2008. http://www.personalizedmedicinecoalition.org/sites/default/files/files/PMC%20Strategic%20Plan%20%203-25-11.pdf.

Arrowsmith

Trial watch. Phase II failures: 2008-2010. Nat Rev Drug Discov. 2011;10:328–329.

Goodsaid

Mendrick

. Translational medicine and the value of biomarker qualification. Sci Transl Med. 2010;2(47):47ps44.

Becker

Jr . Prospective vs non-prospective design in companion drug/diagnostic studies. Presented to the FDA Oncology Drugs Advisory Committee; December 16, 2008. http://www.fda.gov/ohrms/dockets/ac/08/slides/2008-4409s1-00-index.htm.

Sikorski

Yao

. Visualizing the landscape of selection biomarkers in current phase III oncology clinical trials. Sci Transl Med. 2010;2:34ps27.

Lester

. Will personalized medicine help in transforming the business of healthcare? Personalized Medicine. 2009;6(5):555–565. http://www.medscape.com/viewarticle/712541.

Lee

Kohn

. Proteomics as a guiding tool for more effective personalized therapy. Ann Oncol. 2010;21(Suppl 7):vii205–vii210.

Green ED, Guyer MS; National Human Genome Research Institute. Charting a course for genomic medicine from base pairs to bedside. Nature. 2011;470:204–213.

10.

Schmitz

Kaminsky-Forrett

Henry

Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: GORTEC 2008-02. J Clin Oncol. 2010;28:15s (abstract 5500).

11.

Jassem

Langer

Karp

Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer. J Clin Oncol. 2010;28:15s (abstract 7500).

12.

Kwak

Bang

Camidge

Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer. N Engl J Med. 2010;363:1693–1703.

13.

Tarn

Godwin

. Molecular research directions in the management of gastrointestinal stromal tumors. Curr Treat Options Oncol. 2005;6(6):473–486.

14.

Beadling

Jacobson-Dunlop

Hodi

KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res. 2008;14(21):6821–6828.

15.

Min

Liebes

Escalon

Phase II trial of sorafenib in metastatic melanoma (MM) including detection of B-RAF with mutant specific-PCR and altered proliferation pathways: final outcome analysis. J Clin Oncol. 2008;26:abstract 9072.

16.

Flaherty

Puzanov

Kim

Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809–819.

17.

Poulikakos

Zhang

Bollag

Shokat

Rosen

. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464(7287):427.

18.

Miller

. HER2 testing: accuracy remains an issue. Medscape Hematology-Oncology. Posted January 24, 2011. http://www.medscape.com/viewarticle/735991.

19.

Baehner

Achacoso

Maddala

Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories. J Clin Oncol. 2010;28:4300–4306.

20.

Chandarlapaty

Scaltriti

Baselga

Extracellular cleaved HER2 (p95) confers partial resistance to trastuzumab but not HSP90 inhibitors in models of HER2 amplified breast cancer. J Clin Oncol. 2007;25(18S):10515.

21.

Sperinde

Jin

Banerjee

Quantitation of p95HER2, a truncated form of HER2, in FFPE specimens using a p95-specific antibody and correlations with outcome in a cohort of trastuzumab-treated metastatic breast cancer patients. Abstract 56. Proc 2009 Breast Cancer Symp . http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=70&abstractID=40157.

22.

Rosell

Moran

Queralt

Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361:958–967.

23.

Maemondo

Inoue

Kobayashi

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–2388.

24.

Inoue

Kobayashi

Usui

First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol. 2009;27:1394–1400.

25.

Pao

Chmielecki

. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer. 2010;10:760–774.

26.

Zhang

Stiegler

Boggon

Kobayashi

Halmos

. EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget. 2010;1(7):497–514.

27.

Duda

Ancukiewicz

Jain

. Biomarkers of antiangiogenic therapy: how do we move from candidate biomarkers to valid biomarkers? J Clin Oncol. 2010;28(2):183–185.

28.

Hammerman

Sos

Ramos

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous lung cancer. Cancer Discov. 2011;1:78–89.

29.

Dancey

Dobbin

Groshen

Biomarkers Task Force of the NCI Investigational Drug Steering Committee. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res. 2010;16(6):1745–1755.

30.

Freidlin

McShane

Korn

. Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst. 2010;102:152–160.

31.

Mandrekar

Sargent

. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol. 2009;27(24):4027–4034.

32.

US Food and Drug Administration . Innovation or stagnation: challenges and opportunity on the critical path to new medical products. http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html.

33.

Goodsaid

Frueh

. Biomarker qualification pilot process at the US Food and Drug Administration. AAPS J. 2007;9(1):E105–E108.

34.

US Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: qualification process for drug development tools [draft guidance]. Published October 2010. www.c-path.org/pdf/FDADraftDDTools.pdf.

35.

ICH. Final ICH concept paper for topic E16: pharmacogenomic (PG) biomarker qualification: format and data standards. April 17, 2008. EMEA/CHMP/190395/2008; April 17, 2008.

36.

US Food and Drug Administration. Guidance for industry: pharmacogenomic data submissions. http://www.fda.gov/cder/guidance/6400fnl.pdf. Accessed April 19, 2012.

37.

EMA. Final conclusions on the pilot joint EMEA/FDA VXDS experience on qualification of nephrotoxicity biomarkers. January 22, 2009. EMEA/679719/2008:Rev. 1.

38.

EMA. Qualification of novel methodologies for drug development: guidance to applicant. June 30, 2008. EMEA/CHMP/SAWP/72894/2008:Corr1.

39.

EMA. Biomarkers. http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/general/general_content_000349.jsp&murl=menus/special_topics/special_topics.jsp&mid=WC0b01ac05800baedb&jsenabled=true.

40.

EMA. Reflection paper on co-development of pharmacogenomic biomarkers and assays in the context of drug development. June 24, 2010. EMA/CHMP/641298/2008.

41.

European Commission. Directive 98/79/EC, as amended on in vitro diagnostic medical devices. http://ec.europa.eu/enterprise/sectors/medical-devices/regulatory-framework/index_en.htm.

42.

US Food and Drug Administration. Guidance for industry and FDA staff: format for traditional and abbreviated 510(k)s. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/default.htm.

43.

US Food and Drug Administration. PMA guidance documents. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/PremarketSubmissions/PremarketApprovalPMA/ucm143067.htm.

44.

US Food and Drug Administration. New section 513(f)(2). Evaluation of automatic class III designation: guidance for industry and CDRH staff. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm080195.htm.

45.

US Food and Drug Administration. Clinical Laboratory Improvement Amendments (CLIA). http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/IVDRegulatoryAssistance/ucm124105.htm.

46.

US Food and Drug Administration, Center for Devices and Radiological Health. In vitro diagnostic multivariate index assays [draft guidance for industry, clinical laboratories, and FDA staff]. Published July 26, 2007.

47.

Khleif1

Doroshow

Hait

Cancer Biomarkers Collaborative

AACR-FDA-NCI

. AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development. Clin Cancer Res. 2010;16:3299–3318.

48.

Chabner

. Early accelerated approval for highly targeted cancer drugs. N Engl J Med. 2011;364:1087–1089.